A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses

2023-507882-24-00 Protocol 000414 Human pharmacology (Phase I) - First administration to humans Ended

Start 20 Feb 2024 · End 15 Nov 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 000414

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 48
Countries 1
Sites 1

Inflammatory Gastrointestinal Disease

Key facts

Sponsor
Ferring Pharmaceuticals A/S
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
20 Feb 2024 → 15 Nov 2024
Decision date (initial)
2024-02-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-507882-24-00
WHO UTN
U1111-1297-2280

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Inflammatory Gastrointestinal Disease

VersionLevelCodeTermSystem organ class
20.0 HLGT 10017969 Gastrointestinal inflammatory conditions 10017947

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ferring Pharmaceuticals A/S

Sponsor organisation
Ferring Pharmaceuticals A/S
Address
Amager Strandvej 405
City
Kastrup
Postcode
2770
Country
Denmark

Scientific contact point

Organisation
Ferring Pharmaceuticals A/S
Contact name
Arjun Ravi

Public contact point

Organisation
Ferring Pharmaceuticals A/S
Contact name
Clinical and Translational Sciences

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 48 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Charite Research Organisation GmbH
Medical Operations, Chariteplatz 1, Mitte, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-02-20 2024-11-15 2024-03-05 2024-11-15

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-02 Germany Acceptable
2024-02-02
2024-02-08